High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas
Sign Up to like & getrecommendations! Published in 2024 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-024-02394-0
Abstract: Refractory aggressive lymphomas can be treated with allo-SCT, pursuing a graft-vs-lymphoma effect. While reduced intensity conditioning is safe, tumors often progress rapidly, indicating the need for more active conditioning regimens. The preclinical synergy we saw… read more here.
Keywords: aggressive lymphomas; myeloablative regimen; lymphomas; gem clo ... See more keywords